| Literature DB >> 30713712 |
Martin Babor1,2,3, Philipp P Nievergelt2, Jan Čejka1, Vít Zvoníček3,4, Bernhard Spingler2.
Abstract
Multicomponent solid forms of active pharmaceutical ingredients represent a modern method of tuning their physicochemical properties. Typically, salts are the most commonly used multicomponent solid form in the pharmaceutical industry. More than 38% are formulated as organic cations. Salt screening is an essential but demanding step when identifying the most appropriate formulation. The microbatch under-oil crystallization technique of proteins has been combined with the previously developed high-throughput vapour-diffusion screening for use as a novel method of primary salt screening of organic cations. The procedure allows the set up of about 100 crystallization experiments per 30 min. This requires between 17 and 564 mg of screened cationic active pharmaceutical ingredients, which were of moderate to very high water solublity. Five distinct organic salts, three of them diverse active pharmaceutical compounds or the other enantiomer thereof, in the form of chloride salts were tested. The screening was extremely successful; at least two new single-crystal structures could be obtained for each particular compound and many more salts as single crystals were formed compared with our previous vapour-diffusion method.Entities:
Keywords: API; active pharmaceutical ingredients; crystallization; polymorphs; small molecules
Year: 2019 PMID: 30713712 PMCID: PMC6327184 DOI: 10.1107/S2052252518017876
Source DB: PubMed Journal: IUCrJ ISSN: 2052-2525 Impact factor: 4.769
Figure 1Chemical structures of the screened organic cations in the form of chlorides or hydrochlorides.
Screened cations and their aqueous solubility at 22°C
| Approximate solubility (mg ml−1) | Amount needed (mg) | Solution molarity [ | |
|---|---|---|---|
| Diltiazem hydrochloride | 720 ± 70 | 312 | 1.44 |
| ( | 1120 ± 106 | 486 | 5.64 |
| ( | 1300 ± 200 | 564 | 6.54 |
| (1 | 257± 1 | 111 | 1.15 |
| Trazodone hydrochloride | 38.5 ± 0.2 | 17 | 0.085 |
For screening 97 conditions.
At 90% saturation.
Determined as described by Nievergelt et al. (2018 ▸).
Value taken from the work by Nievergelt et al. (2018 ▸).
Obtained single crystals
Crystals were grown by mixing 5 µl of the organic cation solution and 5 µl of the anion solution unless otherwise noted. DX: crystals were observed after X days.
| Salt providing the new anion | Molarity | [(+)-EphH]Cl | [(−)-Car]Cl | [(±)-Car]Cl | [DilH]Cl | [TrazH]Cl |
|---|---|---|---|---|---|---|
| Sodium bromide | 4.08 | D0 | D14 | D5 | ||
| Sodium iodide | 5.34 | D5 | D8 | D11 | D6 | D1 |
| Sodium tetrafluoroborate | 2.00 | D10 | D3 | |||
| Potassium thiocyanate | 7.34 | D2 | D1 | |||
| Sodium nitrate | 4.61 | D30 | D6 | D1 | ||
| Sodium dihydrogen phosphate | 3.40 | D5 | ||||
| Sodium pyrrolidone carboxylate | 4.96 | D1 | ||||
| Sodium benzenesulfonate | 1.10 | D16 | ||||
| Disodium oxalate | 0.138 | D6 | D1 | |||
| Disodium malonate | 2.97 | D16 | ||||
| Sodium | 2.92 | D30 | ||||
| Potassium sodium | 1.40 | D30 | ||||
| No additional salt added | D15 | D14 | D7 | D6 |
Published structure, sometimes of the other enantiomer (Hearn & Bugg, 1972 ▸; Kojić-Prodić et al., 1984 ▸; Collier et al., 2006 ▸; Wu et al., 2012 ▸; Nievergelt et al., 2018 ▸).
Crystallized after touching the drop with a spatula or scratching the well with a dissecting needle.
Obtained by mixing 4 µl of the trazodone solution and 10 µl of the anion solution.
Concentration of sodium tetrafluoroborate was 4.0M.
Obtained by mixing 2 µl of the ephedrine solution and 20 µl of the anion solution.
Two polymorphs (I† and II) observed.
Figure 2Left: displacement ellipsoid representation of [DilH][NO3]. Right: displacement ellipsoid representation of [(−)-Car]Br. Ellipsoids are depicted at 50% probability.
Comparison of the results obtained by under-oil and vapour-diffusion (VDHT) methods
(×): no salt crystal was obtained during the screening. Abbreviations: tetraphenylborate: [TPB]−; thiocyanate: [SCN]−; oxalate: [OXA]2−; benzenesulfonate [BS]−; pyrrolidone carboxylate: [Pyrcarb]−.
| Cation to be crystallized | [(+)-EphH]+ | [(−)-Car]+ | [(±)-Car]+ | [TrazH]Cl | ||||
| Method | Under oil | VDHT | Under oil | VDHT | Under oil | VDHT | Under oil | VDHT |
| Anions | Cl− | Cl− | [TPB]− | [TPB]− | [TPB]− | [TPB]− | I− | I− |
| Br− | Br− | Cl− | × | Cl− | × | [OXA]2− | [OXA]2− | |
| I− | I− | Br− | × | Br− | × | NO3 − | × | |
| [SCN]− | [SCN]− | I− | × | I− | × | [BF4]− | × | |
| [OXA]2− | [OXA]2− | [BF4]−:Cl− | × | [SCN]− | × | |||
| NO3
−
| × | |||||||
| [BS]− | × | |||||||
| [Malonate]2− | × | |||||||
| [ | × | |||||||
| [ | × | |||||||
| [Pyrcarb]− | × | |||||||
Two polymorphs obtained.